Abstract
To date six bona fide death receptors (DRs) have been discovered and include tumor necrosis factor receptor 1 (TNF-R1), Fas, DR3, DR4, DR5 and DR6. Each receptor contains an extracellular region and an intracellular region; the intracellular region harbors a death domain that is critical for transduction of apoptotic signals. These death receptors are activated by their respective ligands. For example, TNFα activates TNF-R1 while FasL and TL1A activate Fas and DR3 respectively. TNF-related apoptosis inducing ligand (TRAIL), also known as Apo2L, activates DR4 and DR5. The ligand for DR6 has yet to be identified. These death receptors are also believed to be activated in a ligand-independent manner. A large body of recent evidence suggests that death receptors could be utilized as key molecular targets to develop novel therapeutics. This review discuses the pros and cons of targeting death receptors in the development of novel cancer therapeutic agents.
Keywords: Cancer Therapeutics, apoptotic
Current Cancer Drug Targets
Title: Death Receptors as Targets of Cancer Therapeutics
Volume: 4 Issue: 1
Author(s): M. Saeed Sheikh and Ying Huang
Affiliation:
Keywords: Cancer Therapeutics, apoptotic
Abstract: To date six bona fide death receptors (DRs) have been discovered and include tumor necrosis factor receptor 1 (TNF-R1), Fas, DR3, DR4, DR5 and DR6. Each receptor contains an extracellular region and an intracellular region; the intracellular region harbors a death domain that is critical for transduction of apoptotic signals. These death receptors are activated by their respective ligands. For example, TNFα activates TNF-R1 while FasL and TL1A activate Fas and DR3 respectively. TNF-related apoptosis inducing ligand (TRAIL), also known as Apo2L, activates DR4 and DR5. The ligand for DR6 has yet to be identified. These death receptors are also believed to be activated in a ligand-independent manner. A large body of recent evidence suggests that death receptors could be utilized as key molecular targets to develop novel therapeutics. This review discuses the pros and cons of targeting death receptors in the development of novel cancer therapeutic agents.
Export Options
About this article
Cite this article as:
Sheikh Saeed M. and Huang Ying, Death Receptors as Targets of Cancer Therapeutics, Current Cancer Drug Targets 2004; 4 (1) . https://dx.doi.org/10.2174/1568009043481597
DOI https://dx.doi.org/10.2174/1568009043481597 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Soft Matter Assemblies as Nanomedicine Platforms for Cancer Chemotherapy: A Journey from Market Products Towards Novel Approaches
Current Topics in Medicinal Chemistry Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine Chylothorax
Current Respiratory Medicine Reviews Microaspiration in Intubated Critically Ill Patients: Diagnosis and Prevention
Infectious Disorders - Drug Targets Molecularly Targeted Therapy for Gastrointestinal Cancer
Current Cancer Drug Targets Can PET Imaging Facilitate Optimization of Cancer Therapies?
Current Pharmaceutical Design Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets Epigenome-Wide Association Studies (EWAS) in Cancer
Current Genomics FDG-PET/CT for Systemic Infections
Current Molecular Imaging (Discontinued) An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020)
Recent Patents on Anti-Cancer Drug Discovery The Extracapsular Lymph Node Extension Predicts Outcomes in Colorectal Cancer: A Short Review
Current Drug Targets Role of Micronutrients: Boron and Molybdenum in Crops and in Human Health and Nutrition
Current Nutrition & Food Science The Significance of Transferrin Receptors in Oncology: the Development of Functional Nano-based Drug Delivery Systems
Current Drug Delivery MIF and CD74 - Suitability as Clinical Biomarkers
Mini-Reviews in Medicinal Chemistry Luminescent Quantum Dots: A Very Attractive and Promising Tool in Biomedicine
Current Medicinal Chemistry Chrysin Induces Apoptosis in Peripheral Blood Lymphocytes Isolated from Human Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer Therapy
Current Medicinal Chemistry Epidermolysis Bullosa: Pediatric Perspectives
Current Pediatric Reviews